Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845188 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL3600152 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL11253251 | 0.91 | ALDH1A1 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL8290690 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL15743850 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL10756834 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL11764943 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL1331012 | 0.88 | TSHR (0.52) | SMN1; SMN2RAB9ANPSR1 | |
| SCHEMBL29816738 | 0.87 | KMT2A (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL20886535 | 0.87 | KMT2A (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-1935435-B1 | Blood pool agents for nuclear magnetic resonance diagnostics | BRACCO IMAGING SPA (IT) | 2017-09-06 | — | — | EP | disclosed |
| US-20100160352-A1 | ADENINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| EP-1140209-B1 | BLOOD POOL AGENTS FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS | BRACCO IMAGING SPA (IT) | 2008-08-20 | — | — | EP | disclosed |
| EP-1935435-A2 | Blood pool agents for nuclear magnetic resonance diagnostics | Bracco Imaging S.p.A (IT) | 2008-06-25 | — | — | EP | disclosed |
| WO-2005100334-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050234065-A1 | Dipeptidyl peptidase-IV inhibitors | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0611371-A1 | PROCESS FOR THE PREPARATION OF CONDENSED IMIDAZOLES | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-08-24 | — | — | EP | disclosed |
| WO-1993009120-A1 | PROCESS FOR THE PREPARATION OF CONDENSED IMIDAZOLES | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234065-A1 | Dipeptidyl peptidase-IV inhibitors | ALPI, DPP4, SI | SMN1; SMN2 1637/4885NPC1 452/4885RAB9A 3052/4885 |
| US-20100160352-A1 | ADENINE DERIVATIVES | HSP90AA1, TRAP1, HSP90AB1 | SMN1; SMN2 3585/4885NPC1 1183/4885RAB9A 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.